Actively Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Led by Takeda · Updated on 2026-03-19
1182
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
CONDITIONS
Official Title
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant is 18 years or older (19 or older in South Korea) at consent
- Completed 52-week treatment in parent study TAK-279-PsA-3001 or TAK-279-PsA-3002 without permanent discontinuation
- Investigator believes participant may benefit from continued or newly started zasocitinib therapy
You will not qualify if you...
- Investigator deems participant not benefiting due to lack of improvement or worsening symptoms in parent study
- Met criteria for permanent discontinuation in parent studies
- Developed diseases confounding benefit evaluation, including rheumatoid arthritis, axial spondyloarthritis (excluding primary PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia
- Developed comorbid skin conditions interfering with study assessments such as non-plaque psoriasis types (erythrodermic, pustular, guttate, inverse, or drug-induced)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First OC Dermatology Research Inc.
Fountain Valley, California, United States, 92708
Actively Recruiting
Research Team
T
Takeda Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here